Review article: hepatitis E—a concise review of virology, epidemiology, clinical presentation and therapy

Alimentary Pharmacology and Therapeutics

Volumn 46, Issue 2, 2017, Pages 126-141

  Donnelly, M C ^a   Scobie, L ^b   Crossan, C L ^b   Dalton, H ^c   Hayes, P C ^a   Simpson, K J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS E VACCINE; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR;

ANTIVIRAL THERAPY; BASIC RESEARCH; BLOOD TRANSFUSION; CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL RESEARCH; DRUG TREATMENT FAILURE; FOOD POISONING; GRAFT RECIPIENT; HEPATITIS E; HEPATITIS E VIRUS; HEPATITIS E VIRUS GENOTYPE 1; HEPATITIS E VIRUS GENOTYPE 2; HEPATITIS E VIRUS GENOTYPE 3; HEPATITIS E VIRUS GENOTYPE 4; HEPATITIS E VIRUS GENOTYPE 7; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION RISK; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT; MOLECULAR BIOLOGY; NONHUMAN; PATIENT EDUCATION; PHYLOGENY; PREGNANCY; PRIORITY JOURNAL; REINFECTION; REVIEW; SYSTEMATIC REVIEW; VIROLOGY; VIRUS DIAGNOSIS; VIRUS TRANSMISSION; ACUTE DISEASE; GENETICS; GENOTYPE; PATHOPHYSIOLOGY; TREATMENT FAILURE;

ACUTE DISEASE; BLOOD TRANSFUSION; FOODBORNE DISEASES; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; RIBAVIRIN; TREATMENT FAILURE;

EID: 85018670619     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14109     Document Type: Review

References (149)

1. Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med. 1980;68:818-824.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-2128.
3. Rein DB, Stevens GA, Theaker J, et al. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012;55:988-997.
4. Peron JM, Bureau C, Porson H, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat. 2007;14:298-303.
5. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med. 2012;367:1237-1244.
6. Viral Hepatitis – Hepatitis E information. Centers for disease control and prevention www.cdc.gov/hepatitis/hev/hevfaq.htm" Accessed March 28, 2017.
7. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:811-817.
8. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140:1481-1489.
9. Holla RP, Ahmad I, Ahmad Z, et al. Molecular virology of hepatitis E virus. Semin Liver Dis. 2013;33:3-14.
10. Suneetha PV, Pischke S, Schlaphoff V, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology. 2012;55:695-708.
11. Nair VP, Anang SA, Subramani C, et al. Endoplasmic reticulum stress induced synthesis of a novel viral factor mediates efficient replication of genotype 1 hepatitis E virus. PLoS Pathog. 2016;12:e1005521.
12. Graff J, Torian U, Nguyen H, et al. A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus. J Virol. 2006;80:5919-5926.
13. Graff J, Nguyen H, Yu C, et al. The open reading frame 3 gene of hepatitis e virus contains a cis-reactive element and encodes a protein required for infection of macaques. J Virol. 2005;79:6680-6689.
14. Emerson SU, Zhang M, Meng X-J, et al. Recombinant hepatitis E virus genomes infectious for primates: importance of capping and discovery of a cis-reactive element. PNAS. 2001;98:15270-15275.
15. Agrawal S, Gupta D, Panda SK. The 3’ end of hepatitis E virus (HEV) genome binds specifically to the viral RNA-dependant RNA polymerase (RdRp). Virol. 2001;282:87-101.
16. Kabrane-Lazizi Y, Meng XJ, Purcell RH, et al. Evidence that the genomic RNA of hepatitis E virus is capped. J Virol. 1999;73:8848-8850.
17. Surjit M, Jameel S, Lal SK. The ORF2 protein of hepatitis E virus binds the 5’ region of viral RNA. J Virol. 2004;78:320-328.
18. Koonin EV, Gorbalenya AE, Purdy MA, et al. Computer-assisted assignment of functional domains in the non-structural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. PNAS. 1992;89:8259-8263.
19. Debing Y, Moradpour D, Neyts J, et al. Update on hepatitis E virology: implications for clinical practice. J Hepatol. 2016;65:200-212.
20. Schofield DJ, Glamann J, Emerson SU, et al. Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol. 2000;74:5548-5555.
21. Li TC, Yamakawa Y, Suzuki K, et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol. 1997;71:7207-7213.
22. Kalia M, Chandra V, Rahman SA, et al. Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. J Virol. 2009;83:12714-12724.
23. Ratra R, Kar-Roy A, Lal SK. The ORF3 protein of hepatitis E virus interacts with hemopexin by means of its 26 amino acid N-terminal hydrophobic domain II. Biochemstry. 2008;47:1957-1969.
24. Moin SM, Panteva M, Jameel S. The hepatitis E virus Orf3 protein protects cells from mitochondrial depolarization and death. J Biol Chem. 2007;282:21124-21133.
25. Chandra V, Kalia M, Hajela K, et al. The ORF3 protein of hepatitis E virus delays degradation of activated growth factor receptors by interacting with CIN85 and blocking formation of the Cbl-CIN85 complex. J Virol. 2010;84:3857-3867.
26. Tyagi S, Korkaya H, Zafrullah M, et al. The phosphorylated form of the ORF3 protein of the hepatitis E virus interacts with its non-glycosylated form of the major capsid protein, ORF2. J Biol Chem. 2002;277:22759-22767.
27. Takahashi M, Yamada K, Hoshino Y, et al. Monoclonal antibodies raised against the ORF3 protein of hepatitis E virus (HEV) can capture HEV particles in cultures supernatant and serum but not those in feces. Arch Virol. 2008;153:1703.
28. Takahashi M, Tanaka T, Takahashi H, et al. Hepatitis E virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. J Clin Microbiol. 2010;48:1112-1125.
29. Nanda SK, Panda SK, Durgapal H, et al. Detection of the negative strand of hepatitis E virus RNA in the livers of experimentally infected rhesus monkeys: evidence for viral replication. J Med Virol. 1994;42:237-240.
30. Zheng ZZ, Miao J, Zhao M, et al. Role of heat-shock protein 90 in hepatitis E virus capsid trafficking. J Gen Virol. 2010;91:1728-1736.
31. Sayed IM, Verhoye L, Cocquerel L, et al. Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. Gut. 2016;66:920-929.
32. van der Garde MDB, Pas SD, van der Net G, et al. Hepatitis E virus (HEV) genotype 3 infection of human liver chimeric mice as a model for chronic HEV infection. J Virol. 2016;90:4394-4401.
33. Allweiss L, Gass S, Giersch K, et al. Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. J Hepatol. 2016;64:1033-1040.
34. International Committee on Virus Taxonomy http://www.ictvonline.org/virustaxonomy.asp Accessed November 09, 2016.
35. Emerson SU, Purcell RH. Hepatitis E virus. Rev Med Virol. 2003;13:145-154.
36. Smith DB, Simmonds P, Izopet J, et al. Proposed reference sequences for hepatitis E virus subtypes. J Gen Virol. 2016;97:537-542.
37. Huang FF, Sun ZF, Emerson SU, et al. Determination and analysis of the complete genomic sequence of avian hepatitis E virus (avian HEV) and attempts to infect rhesus monkeys with avian HEV. J Gen Virol. 2004;85:1609-1618.
38. Scobie L, Dalton HR. Hepatitis E: source and route of infection, clinical manifestations and new developments. J Viral Hepat. 2013;20:1-11.
39. Meng XJ, Halbur PG, Shapiro MS, et al. Genetic and experimental evidence for cross-species infection by swine hepatitis E virus. J Virol. 1998;72:9714-9721.
40. Pavio N, Meng XJ, Doceul V. Zoonotic origin of hepatitis E. Curr Opin Virol. 2015;10:34-41.
41. Tei S, Kitajima N, Takahashi K, et al. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet. 2003;362:371-373.
42. Cossaboom CA, Cordoba L, Dryman BA, et al. Hepatitis E in rabbits, Virginia USA. Emerg Infect Dis. 2011;17:2047-2049.
43. Nidaira M, Takahashi K, Ogura G, et al. Detection and phylogenetic analysis of hepatitis E viruses from mongooses in Okinawa, Japan. J Vet Med Sci. 2012;74:1665-1668.
44. Wang YC, Zhang HY, Xia NS, et al. Prevalence, isolation and partial sequence analysis of hepatitis E virus from domestic animals in China. J Med Virol. 2002;67:516-521.
45. Zhang W, Shen Q, Mou J, et al. Hepatitis E virus infection among domestic animals in eastern China. Zoonoses Public Health. 2008;55:291-298.
46. Crossan C, Baker PJ, Craft J, et al. Hepatitis E virus genotype 3 in shellfish, United Kingdom. Emerg Infect Dis. 2012;18:2085-2087.
47. Brassard J, Gagne MJ, Genereux M, et al. Detection of human food-borne and zoonotic viruses on irrigated, field-grown strawberries. Appl Environ Microbiol. 2012;78:3763-3766.
48. Lee GH, Tan BH, Chi-Yuan Teo E, et al. Chronic infection with camelid hepatitis E virus in a liver transplant recipient who regularly consumes camel meat and milk. Gastroenterology. 2016;150:355-357.
49. Hughes JM, Wilson ME, Teshale EH at al. The two faces of hepatitis E virus. Clin Infect Dis 2010;51:328-334.
50. Khuroo MS, Teli MR, Skidmore S, et al. Incidence and severity of viral hepatitis in pregnancy. Am J Med. 1981;70:252-255.
51. Borkakoti J, Hazam RK, Mohammad A, et al. Does high viral load of hepatitis E virus influence the severity and prognosis of acute liver failure during pregnancy? J Med Virol. 2013;85:620-626.
52. Bose PD, Das BC, Kumar A, et al. High viral load and deregulation of the progesterone receptor signalling pathway: association with hepatitis E-related poor pregnancy outcome. J Hepatol. 2011;54:1107-1113.
53. Sehgal R, Patra S, David P, et al. Impaired monocyte-macrophage functions and defective toll-like receptor signalling in hepatitis E virus-infected pregnant women with acute liver failure. Hepatology. 2015;62:1683-1696.
54. Jilani N, Das BC, Husain SA, et al. Hepatitis E virus infection and fulminant hepatic failure during pregnancy. J Gastroenterol Hepatol. 2007;22:676-682.
55. Bernuau JR, Durand F. Herbal medicines in acute viral hepatitis: a ticket for more trouble. Eur J Gastroenterol Hepatol. 2008;20:161-163.
56. Teshale EH, Howard C, Grytdal S, et al. A large outbreak of hepatitis E in northern Uganda. Emerg Infect Dis. 2010;16:126-129.
57. Sharapov MB, Favarov MO, Yashina TL, et al. Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data. BMC Infect Dis. 2009;9:35.
58. Kumar A, Saraswat VA. Hepatitis E and acute-on-chronic liver failure. J Clin Exp Hepatol. 2013;3:225-230.
59. Kumar Acharya S, Kumar Sharma P, Singh R, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007;46:387-394.
60. Hartl J, Otto B, Madden RG, et al. Hepatitis E seroprevalence in Europe: a meta-analysis. Viruses. 2016;8:211.
61. Ditah I, Ditah F, Devaki P. Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology. 2014;60:815-822.
62. Bendall R, Ellis V, Ijaz S, et al. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol. 2010;82:799-805.
63. Mansuy JM, Bendall R, Legrand-Abravanel F, et al. Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis. 2011;17:2309-2312.
64. Hepatitis E: symptoms, transmission, treatment and prevention https://www.gov.uk/government/publications/hepatitis-e-symptoms-transmission-treatment-and-prevention Accessed November 14, 2016.
65. Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384:1766-1773.
66. Blasco-Perrin H, Madden RG, Stanley A, et al. Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study. Aliment Pharmacol Ther. 2015;42:574-581.
67. Mansuy JM, Gallian P, Dimeglio C, et al. A nationwide survey of hepatitis E viral infection in French blood donors. Hepatology. 2016;63:1145-1154.
68. Renou C, Moreau X, Pariente A, et al. A national survey of acute hepatitis E in France. Aliment Pharmacol Ther. 2008;27:1086-1093.
69. Thom K, Gilhooly P, McGowan K, et al. HEV in Scotland: evidence of recent increase in viral circulation in humans. Unpublished observations. 2016.
70. Farm livestock-Pigs http://www.gov.scot/Topics/Statistics/Browse/Agriculture-Fisheries/agritopics/Pigs Accessed November 14, 2016.
71. Sauleda S, Ong E, Bes M, et al. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). Transfusion. 2015;55:972-979.
72. Stramer SL, Moritz ED, Foster GA, et al. Hepatitis E virus: seroprevalence and frequency of viral RNA detection among US blood donors. Transfusion. 2016;56:481-488.
73. Mansuy JM, Saune K, Rech H, et al. Seroprevalence in blood donors reveals widespread, multi-source exposure to hepatitis E virus, Southern France, October 2011. Euro Surveill. 2015;20:21127.
74. Harritshoj LH, Holm DK, Saekmose SG, et al. Low transfusion transmission of hepatitis E among 25,637 single-donation, nucleic acid-tested blood donors. Transfusion. 2016;56:2225-2232.
75. Passos-Castilho AM, de Sena A, Geraldo A, et al. High prevalence of hepatitis E virus antibodies among blood donors in Southern Brazil. J Med Virol. 2016;88:361-364.
76. Fischer C, Hofmann M, Danzer M, et al. Seroprevalence and incidence of hepatitis E in blood donors in Upper Austria. PLoS ONE. 2015;10:e0119576.
77. Baylis SA, Gartner T, Nick S, et al. Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang. 2012;103:89-90.
78. Vollmer T, Diekmann J, Johne R, et al. Novel approach for detection of hepatitis E virus infection in German blood donors. J Clin Microbiol. 2012;50:2708-2713.
79. Slot E, Hogema BM, Riezebos-Brilman A, et al. Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill. 2013;18:20550.
80. Cleland A, Smith L, Crossan C, et al. Hepatitis E virus in Scottish blood donors. Vox Sang. 2013;105:283-289.
81. Zaaijer HL. No artefact, hepatitis E is emerging. Hepatology. 2015;62:654.
82. Hakze-van der Honing RW, van Coillie E, Antonis AF, et al. First isolation of hepatitis E virus genotype 4 in Europe through swine surveillance in the Netherlands and Belgium. PLoS ONE 2011;6:e22673.
83. Wichmann O, Schimanski S, Koch J, et al. Phylogenetic and case-control study on hepatitis E infection in Germany. J Infect Dis. 2008;198:1732-1741.
84. Tesse S, Lioure B, Fornecker L, et al. Circulation of genotype 4 hepatitis E virus in Europe: first autochthonous hepatitis E infection in France. J Clin Virol. 2012;54:197-200.
85. Garbuglia AR, Scognamiglio P, Petrosillo N, et al. Hepatitis E virus genotype 4 outbreak, Italy, 2011. Emerg Infect Dis. 2013;19:110-114.
86. Servant-Delmas A, Abravanel F, Lefrere JJ, et al. New insights into the natural history of hepatitis E virus infection through a longitudinal study of multitransfused immunocompetent patients in France. J Viral Hepat. 2016;23:569-171.
87. Said B, Ijaz S, Chand MA, et al. Hepatitis E virus in England and Wales: indigenous infection is associated with the consumption of processed pork products. Epidemiol Infect. 2014;142:1467-1475.
88. Denzin N, Borgwardt J. Occurrence and geographical distribution of antibodies to hepatitis E virus in wild boars of Saxont-Anhalt, Germany (2011). Berl Munch Tierarztl Wochenschr. 2013;126:230-235.
89. Dremsek P, Joel S, Baechlein C, et al. Hepatitis E virus seroprevalence of domestic pigs in Germany determined by a novel in-house anf two reference ELISAs. J Virol Methods. 2013;190:11-16.
90. Grierson S, Heaney J, Cheney T, et al. Prevalence of hepatitis E virus infection in pigs at time of slaughter, United Kingdom, 2013. Emerg Infect Dis. 2015;21:1396-1401.
91. Yoo D, Willson P, Pei Y, et al. Prevalence of hepatitis E antibodies in Canadian swine herds and identification of a novel variant of swine hepatitis E virus. Clin Vaccine Immunol. 2001;8:1213-1219.
92. Crossan C, Grierson S, Thomson J, et al. Prevalence of hepatitis E virus in slaughter-age pigs in Scotland. Epidemiol Infect. 2015;143:2237-2240.
93. Maunula L, Kaupke A, Vasickova P, et al. Tracing enteric viruses in the European berry fruit supply chain. Int J Food Microbiol. 2013;167:177-185.
94. Kokkinos P, Kozyra I, Lazic S, et al. Virological quality of irrigation water in leafy green vegetables and berry fruits production chains. Food Environ Virol. 2017;9:72-78.
95. Colson P, Borentain P, Queyriaux B, et al. Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis. 2010;202:825-834.
96. Huang F, Li Y, Yu W, et al. Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis. Hepatology. 2016;64:350-359.
97. Baechlein C, Becher P. No evidence for zoonotic HEV infection through dairy milk in Germany. Hepatology. 2017;65:394-395.
98. Matsubayashi K, Kang JH, Sakata H, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion. 2008;48:1368-1375.
99. Hauser L, Roque-Afonso AM, Beyloune A, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood. 2014;123:796-797.
100. Pischke S, Hiller J, Lutgehetmann M, et al. Blood-borne hepatitis E virus transmission: a relevant risk for immunosuppressed patients. Clin Infect Dis. 2016;63:569-570.
101. Baylis SA, Corman VM, Ong E, et al. Hepatitis E viral loads in plasma pools for fractionation. Transfusion. 2016;56:2532-2537.
102. Schlosser B, Stein A, Neuhaus R, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol. 2012;56:500-502.
103. Pourbaix A, Ouali N, Soussan P, et al. Evidence of hepatitis E virus transmission by renal graft. Transpl Infect Dis. 2017;19:e12624.
104. Ollier L, Tieulie N, Sanderson F, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med. 2009;150:430-431.
105. Dalton HR, Bendall RP, Keane FE, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025-1027.
106. Wu CH, Ho CM, Tsai JH, et al. First case genotype 4 hepatitis E infection after a liver transplant. Exp Clin Transplant. 2017;15:228-230.
107. Kamar N, Rostaing L, Legrand-Abravanel F, et al. How should hepatitis e virus infection be defined in organ-transplant recipients? Am J Transplant. 2013;13:1935-1936.
108. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology. 2010;139:1612-1618.
109. Kuniholm MH, Ong E, Hogema BM, et al. Acute and chronic hepatitis E virus infection in human immunodeficiency virus-infected US women. Hepatology. 2016;63:712-720.
110. Versluis J, Pas SD, Agteresch HJ, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:1079-1086.
111. Pas SD, Streefkerk RHRA, Pronk M, et al. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol. 2013;58:629-634.
112. Emerson SU, Nguyen H, Graff J, et al. In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. J Virol. 2004;78:4838-4846.
113. Kamar N, Izopet J, Cintas P, et al. Hepatitis E virus-induced neurological symptoms in a kidney-transplant patient with chronic hepatitis. Am J Transplant. 2010;10:1321-1324.
114. van den Berg B, van der Eijk AA, Pas SD, et al. Guillain-Barre syndrome associated with preceeding hepatitis E virus infection. Neurology. 2014;82:491-497.
115. Huang S, Zhang X, Jiang H, et al. Profile of acute infectious markers in sporadic hepatitis E. PLoS ONE. 2010;5:e13560.
116. Abravanel F, Chapuy-Regaud S, Lhomme S, et al. Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. J Clin Virol. 2013;58:624-628.
117. Baylis SA, Blumel J, Mizusawa S, et al. World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. Emerg Infect Dis. 2013;19:729-735.
118. Fogeda M, de Ory F, Avellon A, et al. Differential diagnosis of hepatitis E virus, cytomegalovirus and Epstein-Barr virus infection in patients with suspected hepatitis E. J Clin Virol. 2009;45:259-261.
119. Manka P, Bechmann LP, Coombes JD, et al. Hepatitis E virus infection as a possible cause of acute liver failure in Europe. Clin Gastroenterol Hepatol. 2015;13:1836-1842.
120. Crossan CL, Simpson KJ, Craig DG, et al. Hepatitis E virus in patients with acute severe liver injury. World J Hepatol. 2014;6:426-434.
121. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:1429-1435.
122. Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665-1672.
123. Abravanel F, Lhomme S, Chapuy-Regaud S, et al. Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections. J Infect Dis. 2014;209:1900-1906.
124. Baylis SA, Crossan C, Corman VM, et al. Unusual serological response to hepatitis E virus in plasma donors consistent with re-infection. Vox Sang. 2015;109:406-409.
125. Schemmerer M, Rauh C, Jilg W, Wenzel JJ. Time course of hepatitis E-specific antibodies in adults. J Viral Hepat. 2017;24:75-79.
126. Fontana RJ, Engle RE, Scaglione S, et al. The role of hepatitis E virus infection in adult Americans with acute liver failure. Hepatology. 2016;64:1870-1880.
127. Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370:1111-1120.
128. Debing Y, Gisa A, Dallmeier K, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology. 2014;147:1008-1011.
129. Mallet V, Nicand E, Sultanik P, et al. Case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med. 2010;153:85-89.
130. Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int. 2013;33:722-726.
131. Tavitian S, Peron JM, Huguet F, et al. Ribavirin for chronic hepatitis prevention among patients with hematologic malignancies. Emerg Infect Dis. 2015;21:1466-1469.
132. Galante A, Pischke S, Polywka S, et al. Relevance of chronic hepatitis E in liver transplant recipients: a real life setting. Transpl Infect Dis. 2015;17:617-622.
133. Gerolami R, Borentain P, Raissouni F, et al. Treatment of severe acute hepatitis E by ribavirin. J Clin Virol. 2011;52:60-62.
134. Todt D, Gisa A, Radonic A, et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut. 2016;65:1733-1743.
135. Debing Y, Ramiere C, Dallmeier K, et al. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. J Hepatol. 2016;65:499-508.
136. Zhou X, Wang Y, Metselaar HJ, et al. Rapamycin and everolismus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. J Hepatol. 2014;61:746-754.
137. Wang Y, Zhou X, Debing Y, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology. 2014;146:1775-1783.
138. Dao Thi VL, Debing Y, Wu X, et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology. 2016;150:82-85.
139. Donnelly MC, Imlach SN, Abravanel F, et al. Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV/HCV co-infected liver transplant recipient. Gastroenterology. 2017;152:300-301.
140. Brown A, Halliday JS, Swadling L, et al. Characterization of the specificity, functionality and durability of host T-cell responses against the full-length hepatitis E virus. Hepatology. 2016;64:1934-1950.
141. van der Valk M, Zaaijer HL, Kater AP, et al. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E infection. J Hepatol. 2017;66:242-243.
142. Koning L, Charlton MR, Pas SD, et al. Prevalence and clinical consequence of hepatitis E in patients who underwent liver transplantation for chronic hepatitis C in the United States. BMC Infect Dis. 2015;15:371-377.
143. Hepatitis E vaccine pipeline. A document prepared for the Strategic Advisory Group of Experts on Immunization (SAGE) by the Hepatitis E Vaccine Working Group http://www.who.int/immunization/sage/meetings/2014/October/4_Hepatitis_E_vaccine_pipeline_final_29_Sept_14.pdf" Accessed November 21, 2016.
144. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356:895-903.
145. Zhang J, Zhang XF, Huang SJ, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med. 2015;372:914-922.
146. SAGE working group on hepatitis E (October 2013 to December 2014) http://www.who.int/immunization/sage/sage_wg_hep_e_oct13/en/Accessed November 21, 2016.
147. Schielke A, Filter M, Appel B, et al. Thermal stability of hepatitis E virus assessed by a molecular biological approach. Virol J. 2011;8:487.
148. Hepatitis E virus (HEV) and Blood Components. NHS Blood and Transplant http://hospital.blood.co.uk/media/28156/hev-information-for-clinical-htl-staff_final_v11.pdf Accessed November 21, 2016.
149. Advisory Committee on the safety of blood, tissues and organs. Reducing the risk of transfusion-transmitted hepatitis E virus (HEV) infections in patients undergoing solid organ transplantation (SOT) and haematopoetic stem cell transplantation (HSCT) http://hospital.blood.co.uk/media/28241/hev-sabto-recommendations-march-2016.pdf Accessed November 21, 2016.